CSF tau and β-amyloid as biomarkers for mild cognitive impairment

Dialogues in Clinical Neuroscience

Volumn 6, Issue 4, 2004, Pages 379-390

  Hampel, Harald ^a   Blennow, Kaj ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Biochemical marker; Cerebrospinal fluid; Diagnosis; Phosphorylated tau; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GAMMA SECRETASE INHIBITOR; NOOTROPIC AGENT; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; HUMAN; MEMORY DISORDER; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 11144243219     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Blennow K, Skoog I. Genetic testing for Alzheimer's disease: how close is reality? Curr Opin Psychiatry. 1999;12:487-493.
2. Tomlinson BE, Blessed G, Roth M. Observations on brains of demented old people. J Neurol Sci. 1970;11:205-242.
3. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
4. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38:1688-1693.
5. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology and treatment. Lancet Neurol. 2003;2:15-21.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
7. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus Report of the Working Group. Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging. 1998;19:109-116.
8. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Review. Neurobiol Aging. 2003;24:521-536.
9. Masters CL. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245-4249.
10. Haass C, Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell. 1993;75:1039-1042.
11. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733-736.
12. Vassar R, Bennet BD, Babu-Khan S, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-741.
13. Wolfe NS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999;398:513-517.
14. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature. 2000;407:48-54.
15. Francis R, McGrath G, Zhang J, et al. Aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev Cell. 2002;3:85-97.
16. Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002;99:775-779.
17. Miller DL, Papayannopoulos IA, Styles J, et al. Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 1993;301:41-52.
18. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693-4697.
19. Iwatsubo T, Odaka A, Suzuki N, NMizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron. 1994;13:45-53.
20. Tamaoka A, Kondo T, Odaka A, et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β-protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun. 1994;205:834-842.
21. Buėe L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95-130.
22. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49-52.
23. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999;270:91-94.
24. Kohnken R, Buerger K, Zinkowski R, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000;287:187-190.
25. Grundke-Iqbal I, Iqbal K, Tung YC, Quinland M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913-4917.
26. Iqbal K, Alonso AD, Gondal JA, et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm. 2000;59(suppl):213-222.
27. Heine G, Zucht H-D, Schuhmann MU, et al. High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. J Chromatogr B. 2002;782:353-361.
28. Van Nostrand WE, Wagner SL, Shankle WR, et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992;89:2551-2555.
29. Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid β-protein precursor in hereditary Alzheimer's disease. Lancet. 1992;340:453-454.
30. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994;200:1598-1603.
31. van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;37:277-279.
32. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
33. Southwick PC, Yamagata SK, Echols CU, et al. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996;66:259-265.
34. Vanderstichele H, Blennow K, D'Heuvaert ND, et al. Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Press; 1998:773-778.
35. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673-680.
36. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Review. Lancet Neurol. 2003;2:605-613.
37. Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652-656.
38. Otto M, Esselmann H, Schulz-Shaeffer W, et al. Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 2000;54:1099-1102.
39. Sjoegren M, Davidsson P, Wallin A, et al. Decreased CSF β-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dem Geriatr Cogn Disord. 2002;13:112-118.
40. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 2003;18:186-190.
41. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid-β-42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
42. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908-22914.
43. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and A-β42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 1999;273:5-8.
44. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology. 2000;54:1875-1876.
45. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci. 2001;22:77-78.
46. Vanmechelen E, Vanderstichele H, Hulstaert F, et al. Cerebrospinal fluid tau and β-amyloid (1-42) in dementia disorders. Mech Ageing Dev. 2001;122:2005-2011.
47. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology. 1999;52:1555-1562.
48. Sjoegren M, Minthon L, Davidsson P, et al. CSF levels of tau, β-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000;107:563-579.
49. Maruyama M, Arai H, Sugita M, et al. Cerebrospinal fluid amyloid β(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol. 2001;172:433-436.
50. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF β-Amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705-710.
51. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997;148:41-45.
52. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A-β1-40, and A-β1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998;44:17-26.
53. Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF Tau, A-β1-40, A-β1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998;158:134-140.
54. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol. 2000:155-160.
55. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer's disease. Arch Neurol. 2000;57:100-105.
56. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61:1965-1968.
57. Wiltfang J, Esselmann H, Bibl M, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ-peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem. 2002;81:481-496.
58. Lewczuk P, Esselmann H, Meyer M, et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ-peptide. Rapid Commun Mass Spectrom. 2003;17:1291-1296.
59. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828-1834.
60. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231-245.
61. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995;45:788-793.
62. Jensen M, Basun H, Lannfeldt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995;186:189-191.
63. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 1996;212:209-211.
64. Roesler N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;60:237-238.
65. Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997;236:261-264.
66. Arai H, Nakagawa T, Kosaka Y, et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals. Alzheimer's Res. 1997;3:211-213.
67. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995;38:649-652.
68. Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology. 1997;43:2-10.
69. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study [see comments]. J Neurol Neurosurg Psychiatry. 1998;64:298-305.
70. Kurz A, Riemenschneider M, Buch K, et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:372-377.
71. Nishimura T, Takeda M, Nakamura Y, et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol. 1998;20:227-235.
72. Tapiola T, Lehtovirta M, Ramberg J, et al. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 1998;50:169-174.
73. Buerger K, Padberg F, Nolde T, et al. CSF tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease, compared with controls. Neurosci Lett. 1999;277:21-24.
74. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 1999;259:133-135.
75. Hampel H, Teipel SJ, Padberg F, et al. Discriminant power of combined CSF tau and soluble gp130 in the diagnosis of Alzheimer's disease. Brain Res. 1999;823:104-112.
76. Molina L, Touchon J, Herpé M, et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport. 1999;10:3491-3495.
77. Morikawa Y, Arai H, Matsushita S, et al. Cerebrospinal fluid tau protein levels in demented an nondemented alcoholics. Alcohol Clin Exp Res. 1999;23:575-577.
78. Kahle PJ, Jakowec M, Teipel SJ, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 2000;54:1498-1504.
79. Sjoegren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54:1960-1964.
80. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 1995;25:207-217.
81. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997;48:632-635.
82. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995;186:181-183.
83. Blennow K, Vanmechelen E, Hampel H. CSF total tau, A-β42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001;24:87-97.
84. Sjoegren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70:624-630.
85. Sjoegren M, Vanderstichele H, Agren H, et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47:1776-1781.
86. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997;225:210-212.
87. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002;58:192-197.
88. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2001;71:401-403.
89. Kudo T, Mima T, Hashimoto R, et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci. 2000;54:199-202.
90. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187-190.
91. Zemlan FP, Rosenberg WS, Luebbe PA, et al. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999;72:741-750.
92. Mitani K, Furiya Y, Uchihara T, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998;245:44-46.
93. Urakami K, Mori M, Wada K, et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett. 1999;259:127-129.
94. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-A-β-42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
95. Vanmechelen E, Van Kerschaver E, Blennow K, et al. CSF-Phospho tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Disodia S, Winblad B, eds. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester, UK: John Wiley & Sons; 2001.
96. Hu YY, He SS, Wang X, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002;160:1269-1278.
97. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phosphotau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8:343-347.
98. Buerger K, Zinkowski R, Teipel SJ, et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry. 2003;160:376-379.
99. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26-35.
100. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59:1267-1272.
101. Schoenknecht P, Pantel J, Hunt A, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diesase. Neurosci Lett. 2003;339:172-174.
102. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001;50:150-156.
103. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95-102.
104. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627-629.
105. Arai H, Ishiguro K, Ohno H, et al. CSF Phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000;166:201-203.
106. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand. 2003;107:47-51.
107. Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [(123)I] iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry. 2002;159:474-476.
108. de Leon MJ, Segal S, Tarshish CY, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002;333:183-186.